Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ

Core Insights - Hoth Therapeutics, Inc. has announced a collaboration with Washington University School of Medicine to advance Alzheimer's disease research through a novel therapeutic strategy involving HT-ALZ, an FDA-approved NK-1 receptor antagonist [1][4] - The research aims to study the potential of HT-ALZ to reduce neuroinflammation and improve cognitive function in Alzheimer's disease [1][2] Research Collaboration - The collaboration is led by Dr. Carla M. Yuede, focusing on the "Cell Type Specificity of Neurokinin-1 Receptor Antagonists on Cognitive Improvement" [2] - The goal is to understand the neurological mechanisms and cellular targets responsible for the cognitive benefits observed with HT-ALZ [2] Preclinical Studies - Preclinical studies at Washington University showed that chronic oral administration of HT-ALZ significantly improved cognitive functions, reduced anxiety-like behaviors, and decreased neuroinflammation in the APP/PS1 mouse model of Alzheimer's [3] - Acute treatment with HT-ALZ reduced brain interstitial fluid Aβ40 levels by approximately 15% within 20 hours [3] Company Commitment - The CEO of Hoth Therapeutics expressed pride in supporting the research team and emphasized the significance of the grant application in understanding NK-1 receptor biology in neurological diseases [4] - Hoth Therapeutics has supplied GMP-quality HT-ALZ to Washington University to ensure high standards in preclinical research [4] Future Implications - If funded, the grant will further elucidate the cellular specificity of NK-1 receptor antagonism and its implications for treating neuroinflammatory conditions [4]